Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27652127 | 0.74 | GPR119 (0.46) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL27755050 | 0.74 | GPR119 (0.43) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL387943 | 0.74 | GPR119 (0.47) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL387913 | 0.72 | GPR119 (0.48) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL389242 | 0.72 | GPR119 (0.47) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL389113 | 0.72 | GPR119 (0.46) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL388922 | 0.71 | GPR119 (0.46) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL390445 | 0.65 | GPR119 (0.58) | GPR119CYP3A4CYP2C19CNR2GPR183 | |
| SCHEMBL3740574 | 0.63 | GPR119 (0.43) | GPR119CYP3A4CYP2C19CNR2SCN9A | |
| SCHEMBL19454675 | 0.61 | CNR2 (0.44) | GPR119CYP3A4CYP2C19CNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322150-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |